eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2011
vol. 10
 
Share:
Send email
Share:
abstract:
Review paper

The use of micronized progesterone in menopausal hormonal therapy in the light of the most recent study results

Tomasz Paszkowski
,
Ewa Woźniakowska
,
Wojciech Wrona
,
Piotr Szkodziak
,
Tomasz Radomański

Przegląd Menopauzalny 2011; 4: 267–270
Online publish date: 2011/08/30
View full text Get citation
 
Micronized progesterone (MP) can be used in the menopausal hormonal therapy (MHT). Micronized progesterone provides an effective endometrial protection during MHT. Hormonal therapy based on estrogen and vaginal progesterone results in the significant improvement of quality of life, elimination of menopausal symptoms and favorable changes of the blood lipids profile. Micronized progesterone does not adversely affect glucose metabolism and blood pressure. Progesterone seems to be safer for the breast as compared with other progestagens. The most recently published results indicate that MHT based on vaginal MP and transdermal estradiol constitutes the safest option of such therapy.
keywords:

micronized progesterone, menopausal hormonal therapy
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.